Monashee Investment Management LLC 89bio, Inc. Transaction History

Monashee Investment Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$6.66 - $16.03 $932,400 - $2.24 Million	140,000 New	140,000 $1.56 Million
Q1 2023 May 05, 2023	BUY	$10.48 - $16.94 $786,000 - $1.27 Million	75,000 New	75,000 $1.14 Million
Q4 2020 Feb 11, 2021	SELL	$23.16 - $28.08 $926,400 - $1.12 Million	-40,000 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$24.34 - $38.82 $973,600 - $1.55 Million	40,000 New	40,000 $1.03 Million

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $415M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Monashee Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Monashee Investment Management LLC with notifications on news.